Every material Form 8-K PROTHENA CORP PUBLIC LTD CO has filed with the SEC since October 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Prothena reported third-quarter 2026 results with a net loss of $16.5 million, down from $36.5 million in the same quarter of 2025, while quarterly revenue fell to $0.6 million from $2.4 million. For the first nine months, revenue rose to $52.7 million, mainly from a $50.0 million milestone payment from Novo, and the net loss narrowed to $2.4 million from $222.5 million. The company said its 2026 net cash use and year-end cash guidance were unchanged.
Q3 2026 net loss per share was $0.32, versus $0.68 in Q3 2025
Nine-month 2026 revenue included a $50.0 million milestone payment from Novo tied to the coramitug Phase 3 trial
Cash, cash equivalents and restricted cash were $272.2 million at September 30, 2026, with no debt
Prothena repurchased $26.6 million of shares in the first nine months of 2026 under a $100.0 million program expiring December 31, 2026
Bristol Myers Squibb told Prothena on October 28, 2026 that it will not advance PRX019 further in the clinic, and the PRX019 license agreement will terminate on January 28, 2027. Under the terminated agreement, Prothena would have been eligible for up to $617.5 million in milestones and tiered royalties, and Bristol Myers Squibb will owe none of these payments. Prothena's separate moponetug collaboration with Bristol Myers Squibb continues.
Bristol Myers Squibb decided not to advance PRX019 after an internal strategic review, notified Prothena on October 28, 2026.
The PRX019 Global License Agreement, signed in May 2024 with an $80 million upfront payment, terminates on January 28, 2027.
Up to $617.5 million in development, regulatory and sales milestones, plus royalties, will not be paid to Prothena.
Bristol Myers Squibb continues developing moponetug, for which Prothena has received $135 million and is eligible for up to $562.5 million more.
Prothena disclosed that Chief Development Officer Chad J. Swanson, Ph.D., notified the company on October 2, 2026, that he is resigning effective October 9, 2026. He is leaving to join one of Prothena's strategic partners, where he will lead a program partnered with the company.
Chad J. Swanson, Ph.D., Chief Development Officer, resigns effective October 9, 2026.
Notice of resignation was given to the company on October 2, 2026.
Swanson is joining a strategic partner and will lead a program partnered with Prothena.
The filing does not state a successor or interim arrangement.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PROTHENA CORP PUBLIC LTD CO filing is on SEC EDGAR ↗. 8-K briefs of other companies →